Cefadin

Quick links to important sections

Cefadin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefadin

Quick Facts: Cefadin

Property Description
Active Ingredient Cephradine
Pharmacological Class First-Generation Cephalosporin Antibiotic
Origin Semisynthetic
Common Forms Capsules, Oral Suspension, Powder for Injection (IV/IM)
General Purpose Treatment of systemic bacterial infections (bactericidal action)

Cefadin: Classification and Identity of the Active Ingredient

Cefadin is the trade name for the active ingredient Cephradine, a semisynthetic beta-lactam antibiotic used to treat susceptible bacterial infections. It is classified as a first-generation cephalosporin, belonging to a family of agents structurally related to penicillin.

Cephradine's structure is utilized for coverage primarily against many common Gram-positive pathogens and some Gram-negative bacteria, serving as a foundational tool in anti-infective therapy. As a single-ingredient product, it is a prescription-only medicine (POM) intended for systemic use.


Forms, Origin, and General Therapeutic Purpose

Cefadin is available in multiple dosage forms, including oral preparations like capsules and an oral suspension, as well as a sterile powder for injection used for intravenous (IV) or intramuscular (IM) administration. The availability of the oral suspension makes it suitable for patients who may have difficulty swallowing, such as pediatric populations.

Its general therapeutic purpose is to achieve the bactericidal (bacteria-killing) elimination of microorganisms causing an infection. Cephradine's mechanism of action involves the inhibition of bacterial cell wall synthesis, which acts to clear the pathogenic burden. This activity against common bacterial pathogens supports its use in treating various systemic bacterial infections.

What side effects are possible with Cefadin?

Cefadin: Possible Side Effects and Safety Information

Official regulatory documentation organizes the safety profile of Cefadin (Cephradine) by the frequency and physiological system affected, providing a structured view of potential adverse reactions. The medicine's documented effects span multiple System-Organ Classes, primarily involving the gastrointestinal system and immune system.

Frequency-Classified Adverse Reactions

Adverse reactions are classified according to incidence based on clinical data and post-marketing surveillance:

  • Common Reactions generally involve the gastrointestinal system, including diarrhea, nausea, and vomiting. For injectable forms, pain and inflammation at the injection site are commonly documented.
  • Uncommon Reactions may include signs of hypersensitivity such as rash or urticaria, along with general effects like headache and dizziness.
  • Rare Reactions include the potential for serious, systemic events such as anaphylaxis, severe skin reactions, and changes in blood counts like leukopenia or eosinophilia.

Serious Adverse Reactions and Safety Constraints

The most serious adverse reactions listed in regulatory documents include life-threatening anaphylactic reactions and pseudomembranous colitis (a severe form of diarrhea associated with antibiotic use).

Due to the nature of the active ingredient as a beta-lactam, a key safety constraint is the potential for cross-hypersensitivity in individuals with a known allergy to penicillin. Furthermore, as Cephradine is eliminated primarily by the kidneys, the official safety profile emphasizes the need for careful consideration and monitoring in patients with renal impairment due to the risk of increased systemic exposure. The label also notes that Clostridium difficile-associated diarrhea can occur even after the completion of antibiotic therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overexposure to Cefadin (Cephradine) is an officially documented scenario that necessitates immediate medical attention due to the risk of severe complications. Documented overdose presentations commonly include gastrointestinal distress such as nausea, vomiting, and diarrhoea. Other potential systemic manifestations described in regulatory profiles include haematuria (blood in urine) and electrolyte imbalance.

The regulatory documents emphasize the risk of Central Nervous System (CNS) toxicity. Severe outcomes listed include encephalopathy, convulsions (seizures), tremor, and myoclonia. This potential for severe CNS manifestations is noted to be particularly increased in patients with underlying renal impairment.

Required Emergency Action

Regulatory authorities strictly mandate that individuals must seek immediate medical attention following any suspected overexposure, or contact emergency services immediately upon recognizing severe neurological manifestations. Management is limited to symptomatic and supportive treatment, as the official labeling confirms no specific antidote is known. Supportive measures described include gastric lavage, administration of activated charcoal, and measures to control convulsions. Continuous monitoring of vital and renal function is required; hospitalization may be necessary until clinical stability is confirmed.

Therapeutic Uses of Cefadin

Cefadin (Cephradine) is generally considered a relevant antibiotic that provides therapeutic benefit, which is applied in addressing conditions marked by increased physiological stress and managing associated symptoms that interfere with daily functioning. The scope of its application includes therapeutic use in key areas like urinary, respiratory, and skin infections. Its use is relevant in contexts involving heightened systemic burden and localized distress across several key therapeutic domains.


Managing Acute Bacterial Infections

The medication is commonly used to help with conditions presenting with systemic or localized discomfort, such as bacterial tonsillitis, pharyngitis, otitis media, acute bronchitis, cellulitis, abscesses, and urinary tract infections (UTIs). It is applied across domains where additional symptomatic support is needed. In situations where patients experience bacterial infection, it contributes to easing the overall symptom load during periods of heightened symptoms, primarily by supporting the management of fever, sore throat, and localized swelling.

Quick Fact: Relief for Acute Discomfort
Cefadin assists with maintaining functional stability when symptoms linked to organ-specific functional stress (like painful urination or cough) interfere with routine activities.

Regulatory References

  1. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cefadin (Cephradine) — Official Regulatory Information

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults, adolescents, and children older than 9 months are established populations.
Populations for whom use is contraindicated Patients with known Hypersensitivity to Cephradine or any drug in the Cephalosporin class.
Age-related eligibility rules Use is established for children ge 9 months. Older adults require monitoring of renal function.
Condition-specific eligibility rules Use requires caution in patients with impaired renal function (requires dose adjustment) and a history of colitis or other gastrointestinal disease.
Pregnancy and lactation eligibility status Pregnancy is restricted to use only when clearly needed (FDA Category B). Lactation requires caution as the drug is excreted in breast milk.
Eligibility-related restrictions Patients with a history of penicillin allergy require great caution due to potential cross-reactivity.

Eligibility Classifications (High-Level)

Category Official Regulatory Classification
Eligibility severity classification Absolute Contraindication (Hypersensitivity); Conditional Restriction (Renal Impairment, Pregnancy/Lactation); Established Use (Adults, Children ge 9 months).
Regulatory basis Based on Prescribing Information/Summary of Product Characteristics (SmPC) and FDA label documentation.
Eligibility-context constraints Immunological status, Excretory Organ function, and Developmental stage.

Resulting Eligibility Structure

Official eligibility statements:

  • Cefadin is contraindicated in patients with known hypersensitivity to the drug or to any other cephalosporin antibacterial agent.
  • The medication is established for use in adults, adolescents, and pediatric patients older than 9 months.
  • Use in patients with impaired renal function requires caution and a regulatory mandate for dosage adjustment.

Connection to the overall eligibility profile Regulatory documents establish that use of Cefadin is absolutely prohibited in individuals with an allergic history to the cephalosporin class. For populations deemed eligible, conditional use is mandated based on patient status, requiring caution in cases of renal impairment, gastrointestinal disease, a history of penicillin allergy, and during pregnancy or lactation. The official label defines eligibility based on these specific immunological, physiological, and age-related constraints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns for Cefadin (Cephradine) based on pharmacokinetic and pharmacodynamic mechanisms, focusing on altered systemic exposure and additive toxicities.

Documented Pharmacokinetic Interactions

Interacting Substance Official Interaction Pattern Resulting Outcome
Probenecid Competitively inhibits renal tubular secretion. Raises Cephradine serum concentrations by reducing renal clearance.
Zinc-containing products Interfere with oral absorption (chelation). May reduce systemic exposure and effectiveness of Cephradine.

Timing and Administration Restrictions

To prevent interference with absorption, oral products containing zinc (such as multivitamin/mineral supplements) must be administered at least three hours after the dose of Cefadin. The regulatory labeling does not list any combinations as formally contraindicated (prohibited co-administration).

Other Documented Interactions

Loop diuretics (e.g., Furosemide) may increase the potential for nephrotoxicity when co-administered with cephalosporins. Furthermore, Cephradine may decrease the effectiveness of combination-type oral contraceptives and is officially noted as incompatible in parenteral mixtures with active drug substances of high molecular weight.

Mechanism of Action

Cefadin is a beta-lactam antibiotic that exerts its action by interfering with the integrity of the bacterial cell wall. The drug selectively crosses the bacterial cell envelope to access its biological targets, the penicillin-binding proteins (PBPs), which are bacterial transpeptidases. These enzymes are essential for the final stage of peptidoglycan synthesis, a key structural component of the bacterial cell wall. Cefadin binds covalently to the active site of PBPs, thereby irreversibly inhibiting their function.

Inhibition of PBPs blocks the transpeptidation process, preventing the necessary cross-linking of peptidoglycan chains. This molecular event leads to a structurally unstable and defective cell wall, compromising the pathogen's integrity. The resulting mechanical weakness and unchecked autolytic activity induce a massive influx of water across the membrane due to osmotic pressure, culminating in the rapid lysis and clearance of the bacterial cell.

Dosage and Administration Information

The usage of Cefadin (Cephradine) is governed by guidelines detailing administration routes, schedules, and required dosage adjustments. The medicine is available for oral use, via capsules or liquid suspension, and for parenteral use as a sterile powder, administered through intravenous (IV) injection or intramuscular (IM) injection.


Administration Schedules and Dosing

Standard adult oral dosing is typically structured around a time-interval regimen of either twice daily (q 12 hours) or four times daily (q 6 hours), with doses ranging from 250 mg to 500 mg. The maximum daily dose is 4 g for oral administration, or up to 8 g in severe cases via the parenteral route. For instance, surgical prophylaxis involves a high dose administered pre-operatively, followed by subsequent doses at 4- to 6-hour intervals.

Oral formulations may be administered without regard to meals and should be continued for a minimum of 48 to 72 hours after clinical signs of infection resolution. Pediatric dosing is based on body weight (mg/kg/day), with the total daily dose divided into equal, spaced administrations.


Special Procedural Conditions

Specific adjustments are required for certain populations and administration techniques. Patients with renal impairment must have their dosing frequency and amount modified based on their creatinine clearance (CrCl) to maintain proper medication levels. Furthermore, the powder for injection requires reconstitution, and a direct IV dose must be delivered slowly, over a 3 to 5 minute period, to comply with administration standards.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cefadin

Evidence for Use in Urinary Tract Infections (UTIs)

Studies comparing Cefadin to other treatments, including controlled clinical trials, have been conducted for bacterial urinary tract infections (UTIs). These studies have explored how the medicine performs in comparison with other treatments available at the time, and against different dosing schedules for Cefadin itself. The research focused on adult patients with acute, uncomplicated UTIs.

Studies measured the pathogen eradication rates and reported whether the bacteria were absent in the observed populations following the treatment course. They also monitored the pattern of clinical improvement, such as changes in symptoms reported by patients. Findings describe patterns observed in the studies related to short-term clinical outcome, typically assessed shortly after the treatment regimen was completed.

What remains uncertain is the scope of the evidence base. Many key trials are historical studies, meaning they were conducted when the drug was initially developed. Therefore, data comparing Cefadin directly to the current standard-of-care agents used today are often limited. Furthermore, long-term outcomes, such as the pattern of infection recurrence or durability of the response, are not extensively characterized in the primary research.


Evidence for Use in Skin and Soft Tissue Infections (SSTIs)

Cefadin was studied for its application in managing skin and soft tissue infections (SSTIs), including conditions such as cellulitis and abscesses. Research in this area includes controlled clinical trials which explored both adult and pediatric patients with uncomplicated forms of these infections. Studies monitored outcomes related to physical discomfort and the overall clinical response rates observed during the study period.

These studies reported clinical success rates and monitored the pattern of improvement in the localized infection area. Research highlights changes measured during the study period related to the absence of common susceptible pathogens like Staphylococcus and Streptococcus. The evidence base contributes to the broader understanding of first-generation cephalosporins, a class of antibiotics to which Cefadin belongs.


Evidence in Special Populations and Research Gaps

Cefadin was studied for use in children with infections such as otitis media and pharyngitis. Studies focusing on these episodes where symptoms become more noticeable have examined how symptoms evolved in the observed young populations.

The research on Cefadin contributes to the broader evidence landscape but also highlights several areas where certainty remains low. The evidence quality varies across studies, with many being historical and having modest sample sizes. A key uncertainty is the lack of current, large-scale comparative evidence against modern antibiotics. As a result, the results apply only to the populations studied and do not determine whether an individual will respond similarly.

Key Studies & References

  1. Cephalosporin Antibiotics: StatPearls [Review of First-Generation Class Evidence and Uses]
  2. Health Products Regulatory Authority (HPRA) Summary of Product Characteristics for Cephradine (Regulatory Document)

Frequently Asked Questions (FAQ)

Common questions about Cefadin (FAQ)


Q: How quickly does Cefadin start working after taking it?

Studies examining how the body handles the medicine indicate that the active ingredient reaches its highest concentration in the blood within approximately 1 to 1.5 hours after it is taken orally. This documented time-to-peak concentration is the point at which the medicine achieves its maximal systemic exposure.


Q: What are the most common reasons a doctor prescribes Cefadin?

The official documented uses in prescribing information focus on treating specific infections caused by susceptible bacteria. These commonly include bacterial infections of the urinary tract, pharynx (throat), and skin and soft tissues.


Q: What is the general duration of treatment for Cefadin?

Cefadin is a short-course antibiotic. The documented treatment duration often ranges from 5 to 10 days for many common bacterial infections. However, the exact duration for specific conditions, like pyelonephritis, may extend to approximately 14 days, according to official dosing guidelines.


Q: What happens if I stop taking Cefadin earlier than suggested?

Regulatory documents specify that treatment should continue for a minimum, predefined duration to eliminate the infection. Stopping the medicine earlier than the prescribed duration has been associated with the potential for incomplete eradication of the bacterial infection.


Q: What is the risk of an allergic reaction to Cefadin if I am allergic to penicillin?

Official safety constraints emphasize the potential for cross-hypersensitivity (cross-reactivity) in individuals who have a known allergy to penicillin. The official safety profile notes that caution is warranted for individuals with such a history.


Q: Can Cefadin be taken with antacids?

Official labeling documents state that oral products containing zinc may interfere with the absorption of Cefadin, which could potentially reduce its effectiveness. Official documentation specifies that zinc-containing products are to be separated from the Cefadin dose by at least three hours to prevent this interaction.


Q: What are the most serious drug interactions listed for Cefadin?

Documented interactions include those that may affect the concentration of Cefadin in the blood, such as Probenecid. Combining the medicine with certain diuretic agents may also increase the potential for effects on the kidneys. These interactions emphasize that the use of these drug combinations warrants clinical monitoring.


Q: Is it okay to drive or operate machinery while taking Cefadin?

Official adverse reaction documents list dizziness as an uncommon documented side effect. Since dizziness is an effect that may temporarily affect alertness, the official safety documentation emphasizes that patient awareness of this risk is important before performing tasks that require concentration.


Q: Can Cefadin cause stomach upset or nausea?

Yes, nausea and vomiting are listed among the common adverse events documented in clinical data and official post-marketing surveillance. Diarrhea is also commonly reported as a gastrointestinal effect.


Q: Do food or certain types of drinks affect how Cefadin works?

The official labeling specifies that the oral formulations of Cefadin may be administered without regard to meals. This means that food intake is not noted as significantly impacting the medicine's action or absorption.


Q: Is Cefadin considered a long-term or short-term medication?

Official dosing schedules are defined for specific short-course treatment durations, typically lasting no more than 14 days. This usage pattern indicates that it is an antibacterial agent prescribed for short-term use.


Q: How does Cefadin relate to other 'cef' drugs, like cephalexin?

Cefadin (Cephradine) is officially classified as a first-generation cephalosporin antibiotic. This places it in the same pharmacological class as other 'cef' drugs, such as cephalexin, meaning they share similar documented mechanisms of action.


Q: Are there dietary restrictions when taking Cefadin?

The official labeling does not specify general dietary restrictions related to food. However, it does require a specific timing separation from products containing zinc to avoid reduced absorption, as this is a documented drug interaction.


Q: Can I use Cefadin if I have a history of liver disease?

The official prescribing information highlights the importance of monitoring organ function, with specific requirements for adjusting the dose in patients with impaired kidney function. Organ function, including that of the liver, is a component of the patient's physiological profile that is assessed before prescribing.


Q: How long does Cefadin stay in your system after the last dose?

The medicine is rapidly processed by the body. The documented elimination half-life—the time it takes for the concentration to reduce by half—is approximately 0.5 to 1.5 hours.


Q: Is Cefadin effective against viruses?

No. Cefadin is officially classified as a beta-lactam antibiotic and its documented purpose is the treatment of susceptible bacterial infections. It is not indicated for infections caused by viruses.


Q: Does Cefadin interact with common pain relievers like ibuprofen or acetaminophen?

The official regulatory interaction checker does not list a specific interaction with ibuprofen. However, the potential interaction with acetaminophen (paracetamol) is classified as one that warrants monitoring by a healthcare professional.


Q: Are there any known side effects that only affect men or women?

Documented side effects include genitourinary events, such as vaginal yeast infections or vaginal discharge, which are effects observed in the female patient population.


Q: Can Cefadin affect my mental state or mood?

Official adverse reaction documentation lists effects on the nervous system, such as dizziness and headache. These effects may be perceived as impacting mental state or general well-being.


Q: How is Cefadin eliminated from the body?

The medicine is primarily eliminated from the body through the kidneys. The process involves the excretion of the unchanged drug into the urine, which is why monitoring kidney function is often emphasized in official labeling.


Q: Is Cefadin used in combination with other medicines sometimes?

The labeling notes incompatibility rules for mixing injectable solutions (parenteral mixtures) with certain other drug substances. Outside of this, the official documentation focuses on specific interactions when Cefadin is co-administered with other medicines.


Q: Why are antibiotics like Cefadin sometimes given before surgery?

Official documentation describes a specific procedure known as surgical prophylaxis. This involves administering a high dose of the antibiotic pre-operatively (before surgery) as a strategy to help prevent potential infection at the surgical site.


Q: Can Cefadin interact with alcohol?

Official guidance for the cephalosporin class of antibiotics notes that consuming alcohol may rarely lead to a specific adverse reaction known as a disulfiram-like reaction. The possibility of this reaction warrants attention when assessing alcohol consumption during treatment.


Q: Can Cefadin cause drowsiness?

The official adverse reaction documentation lists dizziness as an uncommon documented side effect. While dizziness is not the same as drowsiness, it is a related central nervous system effect that may temporarily impact alertness.

How should Cefadin be stored and disposed of?

Storage and Disposal of Cefadin (Cephradine) — Official Regulatory Information

Requirement Official Labeled Condition
Storage Temperature Unmixed forms must be stored at Controlled Room Temperature (20 C-25 C). Reconstituted oral suspension requires refrigeration (2 C-8 C).
Protection & Handling Powder for injection must be Protected from Light. The oral suspension powder must be kept tightly closed. Reconstituted suspension must not be frozen.
Stability After Mixing The refrigerated oral suspension is stable for 7 days and must be discarded after that period. Reconstituted injection solutions have a short stability period, typically 12 hours when refrigerated, and must be used promptly.
Disposal All medicines must be kept out of the sight and reach of children. Unused or expired Cefadin should not be disposed of via wastewater or household waste but must follow local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefadin found in:

A-Z Index: